Genentech doubles down on its PhIII Alzheimer’s campaign for crenezumab
Roche’s big biotech group Genentech is doubling down on one of the most prominent drugs in late-stage development for Alzheimer’s. The company is launching a second Phase III study of crenezumab, according to its partners at AC Immune $ACIU, in search of positive data in a field littered with the wreckage of earlier clinical crashes.
Investigators for the CREAD2 study will now set out to recruit 750 patients with prodromal or mild Alzheimer’s to test the drug, another anti-amyloid beta drug designed to sweep out toxic formations that are believed by many to cause the memory-wasting illness.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.